Drugs / ciclophosphamide
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00849355 | Aug 2008 → Nov 2009 | B-cell non-Hodgkin lymphoma | Asociacion Doctor Peset Para el Estudio de la Hematología | Unknown | No outcome recorded |
| Phase 2 | NCT01361191 | Jun 2007 → Sep 2012 | diffuse large B-cell lymphoma | Spanish Lymphoma Cooperative Group | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00174707 | Dec 1997 → Dec 2007 | breast neoplasm | Sanofi | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02036489 | Jan 2008 → Dec 2019 | acute lymphoblastic leukemia | PETHEMA Foundation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ciclophosphamide | “Treatment: rituximab 375m/m2 + ciclophosphamide 750 mg/m2 + Vincristine 1.4 mg/m2 + Doxorrubicine 50 mg/m2 at day 1 and every 14d.” NCT00849355 ↗ |
| Known as | cyclophosphamide | “1,000 mg/m2 cyclophosphamide , i.v. day 36” NCT02036489 ↗ |
| Route | Intravenous | “1500 mg/m2, IV, day 1” NCT01361191 ↗ |